Obtaining optimal pulmonary vein (PV) occlusion with the endoscopic laser balloon ablation system (EAS) can be difficult, hypothetically influenced by PV geometry. The aim of this study was to determine the impact of PV orientation on atrial fibrillation (AF)-free survival after PV isolation (PVI) using the EAS.
Introduction
Pulmonary vein isolation (PVI) is an effective treatment for atrial fibrillation (AF), 1, 2 although it is hampered by relatively frequent AF recurrences after long-term follow-up. 3, 4 Pulmonary vein (PV)
anatomy, such as common PVs, accessory PVs, and PV ovality, has been shown to influence long-term PVI efficacy in multiple PVI techniques. 5 -7 Endoscopic laser balloon ablation system (EAS) is a relatively novel and promising technique for PVI, 8 although obtaining optimal PV occlusion with the EAS can be difficult. Hypothetically, PV geometrical characteristics, such as PV orientation, may influence catheter placement and the creation of durable lesion sets. The aim of this study was to determine the association between PV orientation and AF-free survival in patients with AF undergoing PVI using the EAS.
Methods
Data from forty-three consecutive patients suffering from highly symptomatic, drug-refractory AF who underwent a first PVI using the EAS were collected in a prospective registry. Exclusion criteria were a previous PVI attempt, left atrium (LA) diameter exceeding 50 mm in the parasternal long-axis view, severe valvular heart disease, and contraindications to postinterventional oral anticoagulation. Directly prior to the ablation procedure, all patients underwent transoesophageal echocardiography to rule out LA thrombus.
Computed tomography characteristics
All patients underwent computed tomography (CT) scanning of the LA to guide the procedure. Cardiac multislice CT (MSCT) angiography was performed by a team of very experienced CT technologists using a 64-slice scanner (Lightspeed VCT XT, GE Healthcare). A bolus of 70 mL of non-ionic contrast medium of agent (Optiray 350, Mallinckrodt, The Netherlands) was infused through a large antecubital vein at a rate of 5 mL/s, followed by 50-mL saline solution flush. Automatic detection of the contrast bolus in the LA was used to time the start of the scan. Delay times varied significantly because of flow rate differences in patients but were generally in the range of 5 -15 s. Craniocaudal scanning was performed during breath-hold and using retrospective electrocardiogram (ECG) gating (to be able to determine volume changes of the LA, but not used in this study). The collimation was 64 × 0.5 mm, rotation time was 400 ms, and the tube voltage was 120 kV with mA dose modulation variable between 80 and 200 mA. All images were checked for adequacy before the end of the procedure to guarantee adequate image quality in all patients. In accordance with local guidelines, PV analysis was performed at 40% of the RR interval, to ensure maximum contrast enhancement in the atrium. After acquisition, the raw MSCT data were exported, post-processed, and analyzed on a dedicated workstation (GE Healthcare). The images were reviewed by an independent investigator who was not involved in the EAS ablation procedures and was not informed about the PVI outcome in these patients to prevent unconscious bias.
PV orientation measurement
The PV trunk orientation measurement has been described in previously published reports. 9, 10 The orientation of the PV trunk at the site of insertion into the LA was assessed for all PVs in both the transverse and frontal (coronal) plane. A line was drawn in the direction of each PV trunk in both the transverse and frontal plane. Thereafter, the angle between the PV trunk direction and the intersection line of the sagittal plane was measured in the transverse and frontal plane (Figure 1) . Median PV trunk angles were calculated in the transverse and frontal plane for all four PV trunks. PVs were assigned to a ventral/dorsal or caudal/cranial orientation depending on the PV trunk angle compared with the median angle. So, each PV trunk was assigned to one of the four orientation groups: ventral-caudal, dorsal-caudal, ventral-cranial, and dorsal-cranial. Common PVs 11 were excluded from analysis. Figure 1 Example of RLPV orientation measurement in the frontal plane. This figure displays the PV orientation measurement in the frontal and transverse plane of the RLPV. As displayed in A, the angle between the PV and the sagittal plane reference is 778 in the frontal plane. The median RLPV direction is 828 in the frontal plane, as can be observed in Table 2 , categorizing the RLPV in this patient to the caudal RLPV orientation group, as displayed in B. As displayed in C, the angle between the PV and the sagittal plane reference is 1228 in the transverse plane. The median RLPV direction is 588 in the transverse plane, as can be observed in Table 2 , categorizing the RLPV in this patient to the ventral RLPV orientation group, as displayed in D.
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Endoscopic laser balloon ablation
The EAS (CardioFocus, Marlborough, MA, USA) is a non-steerable, compliant balloon catheter that is designed to perform isolation of PVs between 9 and 32 mm. Its characteristics have been described previously. 12, 13 
Electrophysiological procedure
All ablation procedures were performed under general anaesthesia supervised by a cardiovascular anaesthesiologist. Two operators performed the EAS ablation procedures, both very experienced with .1000 previous PVIs and .25 EAS ablations. After placement of a 6F quadripolar catheter in the coronary sinus, two transseptal punctures were performed using a Brockenbrough needle under fluoroscopic and pressure guidance. After the first transseptal puncture, 10 000 IU of unfractionated heparin was administered. After two transseptal punctures, an 8.5F sheath (SL-1, St Jude Medical, Minnetonka, MN, USA) was used for the introduction of a circular mapping catheter and a 10F sheath (SL-1, St Jude Medical) was used for PV angiography. All sheaths were continuously flushed with saline containing 2500 IU heparin per 500 mL saline. An activated clotting time between 300 and 350 s was targeted. The activated clotting time was checked during the procedure at regular intervals of 30 min. Additional heparin was administered when needed. PV angiography was performed to identify the locations of the PVs. The 10F transseptal sheath was then exchanged using a guidewire placed in the left upper PV (LUPV) for a 12F (CardioFocus) steerable sheath. The EAS was inserted through the 12F sheath, and the decapolar circular mapping catheter (Lasso w , Biosense Webster Inc., Diamond Bar, CA, USA) was inserted through the 8.5F sheath. Templates of electrical signals in all PVs were acquired using the circular mapping catheter. An oesophageal temperature probe (SensiTherm, St Jude Medical) was inserted, and energy delivery was instantaneously terminated when temperature exceeded 39.08C. During ablation of the right-sided PVs, stimulation of the phrenic nerve (using 20 mA at 2.0 ms) was performed, with immediate cessation of energy delivery once capture was diminished or lost.
The EAS was maneuvered to each PV ostium, and PV occlusion was attempted by varying the balloon inflation size until a ring of atrial myocardium antral to the PV was exposed. Laser energy was delivered to the exposed ring of atrial tissue. The ablation circle was completed after 'controlled rotation' by carefully rotating the EAS to expose the previously obscured atrial tissue, i.e. blind spot. After a full circle was completed, persistent electrical disconnection between the PV and the LA was assessed with the circular mapping catheter. If any electrical conduction between the LA and the PV existed, the EAS was re-introduced to the PV, and additional lesions were applied by the operator.
Postprocedural care
Oral anticoagulants were resumed immediately after the procedure, with a target INR of 2.5-3.5, in accordance with local guidelines. Low molecular weight heparin was administered in a patient weight-dependent dose until INR was adequate.
Follow-up
A blanking period of 3 months was defined after PVI. Patients visited the outpatient clinic at 3, 6, 12, 18, and 24 months after PVI, including 24-h Holter ECG. Patients were immediately referred to the emergency room in case of symptoms. Three months after PVI, an attempt was made in all patients to cease anti-arrhythmic drugs (AADs).
Study end points
The primary end point of our study was AF-free survival, defined as patients without AF recurrence after a postablation blanking period of 3 months. AF recurrence was defined as an ECG showing the characteristics of AF, or on a 30 s telemetry strip, in accordance with European AF ablation guidelines. 2 
Statistical analysis
Continuous data were expressed as mean + standard deviation in case of normal distribution or median + inter-quartile range when variables were not normally distributed. The association between AF-free survival and PV orientation was assessed with a log-rank test. Uni-and multivariate Cox proportional hazard models were used to determine predictors of AF-free survival. The pool of variables considered were those found to be significant at P , 0.100 in univariate analysis. In multivariate analyses, a significance level of 0.050 was maintained. Statistical analysis was performed using IBM SPSS statistics version 20 (IBM inc., Armonk, NY, USA). A P-value of ≤0.05 was considered statistically significant. 
Results
The study population consisted of 43 consecutive patients. Table 1 describes the baseline characteristics. All CT scans were of adequate quality that allowed PV orientation measurement. There were three left common PVs (1.7%), which were excluded from analysis. There were no accessory PVs or right common PVs. No LA thrombi were found during pre-operative transoesophageal echocardiography. Table 2 describes the characteristics of the PV orientation in all patients.
Procedural characteristics
In 172 out of 173 PVs (99.4%), acute PV isolation after EAS ablation was confirmed. In one patient, EAS was converted to conventional radiofrequency catheter ablation after the occurrence of a temporary phrenic nerve paralysis during isolation of the right-sided PVs.
PV orientation and AF-free survival
Median follow-up was 18.2 months (inter-quartile range 14.3 -19.8).
Overall, AF-free survival was 51.2% after a single EAS PVI procedure without the use of Class I or III AADs. LUPV orientation was associated with AF-free survival (P ¼ 0.045). AF-free survival was 21.4% in the ventral-caudal LUPV orientation group, compared with 87.5% in the dorsal-cranial LUPV orientation group, as displayed in Figure 2 . Furthermore, left lower PV (LLPV) orientation was also significantly associated with AF-free survival. AF-free survival was 21% in patients with ventral-caudal and 86% in patients with dorsal-cranial orientation Figure 2 Association between PV orientation and AF-free survival. This figure displays the association between PV orientation and AF-free survival for all four PVs (log-rank test). The lines represent the % of patients who are AF-free and off AADs. There is a significant association between LUPV and LLPV orientation and AF-free survival. P-value between PV orientation groups.
of the LLPV (P ¼ 0.010). In Figure 3 , the difference between a dorsal-cranial LLPV orientation is compared with a ventral-caudal LLPV orientation. Right upper PV (RUPV) orientation was not associated with AF-free survival after EAS PVI, as displayed in Figure 2 and Table 3 . Although not significant, right lower PV (RLPV) orientation seemed to be associated with AF-free survival (P ¼ 0.053). AF-free survival ranged between 29 and 88%, depending on RLPV orientation.
Univariate and multivariate analysis
Univariate analysis showed a significant association between AF-free survival and LUPV and LLPV orientation. Of note, there seemed to be a difference between the ventral-caudal orientation group and the dorsal-cranial orientation group for both the LUPV [hazards ratio (HR) 10.1, P ¼ 0.028] and the LLPV (HR 10.8, P ¼ 0.024), as displayed in Table 3 . Furthermore, although univariate analysis does not show a significant association between RLPV and AF-free survival (P ¼ 0.104), there is a significant difference between the dorsalcranial RLPV orientation group and the dorsal-caudal RLPV orientation group (HR 9.0, P ¼ 0.037). Of all baseline characteristics, only persistent AF showed a significant association with AF-free survival (HR 2.7, P ¼ 0.051). In multivariate analysis, only LLPV orientation and AF type were significantly associated with AF-free survival, as displayed in Table 3 .
Discussion
This is, to our knowledge, the first study showing an association between PV orientation and AF-free survival after endoscopic laser balloon PVI. AF-free survival was significantly associated with LUPV and LLPV orientation, and there may be an association between AF-free survival and RLPV orientation. RUPV orientation was not Relevance of pulmonary vein orientation associated with AF-free survival. These findings suggest that PV orientation assessment may be useful in selecting the most suitable patient for EAS PVI.
PV anatomy and AF-free survival
In a previous report on 51 patients undergoing EAS PVI, an association between PV diameter, PV ostium shape, and PV branching level and AF-free survival was not found.
14 However, in cryoballoon ablation, PV ovality 6 and branching level were shown to influence AF-free survival. 15 Moreover, in both cryoballoon and radiofrequency catheter ablation, an atypical PV anatomy, such as common ostium and accessory PVs, was shown to influence AF-free survival after PVI. 5, 7 However, none of these studies investigated the impact of PV orientation on AF-free survival.
PV orientation measurement
Previous studies 9,10 described the PV orientation method used in the present study. However, no studies reported the association between EAS and PV orientation. Moreover, in this study, PV orientation was measured in the transverse and frontal plane separately. In the present study, PV orientations were categorized into four anatomical groups, combining the PV orientation in the transverse and frontal plane, thus allowing for a more specific categorization.
EAS characteristics
The EAS was designed to overcome limitations of radiofrequency catheter ablation and cryoballoon ablation. The EAS consists of a compliant balloon, overcoming previously mentioned disadvantages of the non-compliant cryoballoon and allowing ablation of PVs with a diameter varying from 9 to 35 mm with a single balloon. Furthermore, it consists of a power adjustable laser beam, with variable power settings and an endoscope, allowing visualization of the PV antrum and facilitating adequate targeting of atrial tissue located at the PV antrum. However, obtaining a PV antrum exposure of 3608 could not be achieved in all patients, and the EAS necessitates 'controlled rotation' in almost all PVs. Potential mechanisms of association between PV orientation and AF-free survival
Despite achieving acute isolation in 99.4% of PVs, the overall AF-free survival after ablation in this patient population was 51.2% after a median follow-up of 18.2 months. AF recurrence is generally considered a sign of local electrical reconnection between the LA and PV. 16, 17 Creating durable PV lesion sets is therefore important in achieving long-term AF-free survival. PV orientation may affect the creation of durable PV lesion sets, by influencing deployment of the EAS in the PV. One may speculate that EAS deployment may be suboptimal depending on PV orientation, implicating that exposure of the target PV antral tissue is occasionally obscured by a blood pool. As mentioned earlier, ablation close to a blood pool necessitates a reduction in energy settings and may produce less durable lesions. In a recent study, 18 high-dose laser ablation resulted in a higher AF-free survival compared with low-dose ablation. Potentially, PV orientation necessitates a reduction in energy settings in selected PV orientation groups and thereby influences AF-free survival. Potentially, a dorsal orientation of the LLPV may allow a more fluent pathway compared with a ventral orientation, with the catheter system approaching from the right atrium, through the interatrial septum and deployed in the LLPV. Hypothetically, a more fluent pathway allows for an improved deployment of the EAS in the PV. Interestingly, a dorsal-caudal and dorsal-cranial orientation of the LLPV was associated with a higher AF-free survival compared with a ventral-caudal or ventral-cranial LLPV orientation (Figure 2) .
PV anatomy and AF substrate
Several previous studies reported the influence of AF on LA and PV anatomy. Kato et al. 19 showed that AF was associated with an increased PV length compared with control patients. Moreover, LA geometrical characteristics, such as LA size 20 -23 and LA fibrosis, 24, 25 are altered in patients with AF. An increased LA size is usually associated with an increased AF substrate. Potentially, PV orientation is influenced by the LA size, and this may explain the association between PV orientation and AF-free survival. However, this study was not designed to identify the mechanism behind the association between PV orientation and AF substrate.
Future direction
Although this study found a significant association between LUPV and LLPV orientation and AF-free survival, this study lacked sufficient statistical power to demonstrate a significant association between RLPV orientation and AF-free survival. Moreover, increased statistical power may also demonstrate a significant association in multivariate analysis. A larger study may also help to determine the mechanism for the association and the exact PV orientation cut-off values that have a substantial impact on AF-free survival.
There is also a clear need to determine the association between PV orientation and AF-free survival in other PVI techniques. Potentially, pre-ablation assessment of PV orientation can aid in determining the most suitable PVI technique. This may improve overall AF-free survival after PVI.
Limitations
With regards to interpreting our data, the following limitations should be considered. This is a single centre study with a limited number of patients and was not designed to differentiate whether the influence of PV orientation on AF-free survival is due to factors related to the PVI technique or differences in AF substrate. PV orientation was assessed with retrospective gating, thus increasing the overall radiation exposure. The patient population with AF recurrence after PVI who underwent a second PVI attempt after failed EAS ablation was too small to draw conclusions regarding PV orientation and PV reconnection.
Conclusion
In this study, PV orientation was associated with AF-free survival in patients undergoing EAS PVI. Whether this is related to the ablation technique or other factors remains to be delineated. Potentially, PV orientation measurement is an important tool in predicting AF-free survival after PVI, and PV orientation assessment may allow operators to tailor ablation therapy by selecting the PVI technique most suitable for each patient's PV anatomy.
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